Loading
Idexx Laboratories INC /de Stock: price and insider trades · United States
Idexx Laboratories INC /de: what insiders have been doing
Every trade that managers of Idexx Laboratories INC /de disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Westbrook, United States. It was founded in 1983. 14 insiders have disclosed 26 filings since 18 October 2025.
The flow runs one way only: 3 sales worth €3.5M, from 2 insiders, and no purchase. One trade stands out by size: a sale of €1.5M from Hunt Nimrata, disclosed on 27 February 2026.
Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,458 companies, median 22 filings), a count of 26 filings is above the norm. Since 2016, the database holds no purchases and 21 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 4.30 bn USD of revenue and 1.06 bn USD of net income.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
241
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€13M
21 ops. · all time
Who traded when
BuySaleNimrata Hunt3 sales
Lawrence D. Kingsley1 sale
Michael G. Erickson1 sale
Szostak M Anne1 sale
Analyst consensus: bullish or bearish?
Analysts rate Idexx Laboratories INC /de Buy (bullish), based on 12 analysts. Average price target: US$705.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,338 of 24,148 companies
61.4
score / 100
Value37
Quality86
FCF yld2.4%
Earn yld2.4%
EV/EBITDA30.0x
ROE74%
Gross mgn62%
Net mgn25%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$560.36
Analyst consensus
12 analystsBuy
US$470.00Target US$705.50(+26%)US$805.00
Income statement
RevenueUS$4.3B
Gross profitUS$2.7B62% margin
EBITDAUS$1.5B35% margin
Net incomeUS$1.1B25.0% margin
Valuation
PER (trailing)39.8x
PER (forward)33.4x
P/Book27.4x
Beta1.55
Balance sheet & cash
Market capUS$44.2B
Total debtUS$976.1M
Free Cash FlowUS$1B
Debt / Equity68%
Profitability & ownership
ROE74.2%
ROA27.1%
% insiders0.2%
% institutions96.6%
Last declaration on 9 September 2026
Declarations241 total
2,203 shares@ US$114.170.0006% mcap17.7% of flowCommon StockSEC:0000874716-26-000127:0
2,203 shares@ US$532.08260.0028% mcap82.3% of flowCommon StockSEC:0000874716-26-000127:1
2,203 shares@ US$532.0827100.0% of flowCommonSEC144:0001950047-26-009112
265 shares@ US$178.260.0001% mcap15.3% of flowCommon StockSEC:0000874716-26-000125:0
86 shares0Common StockSEC:0000874716-26-000125:1
49 shares@ US$558.800.0001% mcap36.6% of flowCommon StockSEC:0000874716-26-000117:0
197 shares@ US$505.536.4% of flowCommon StockSEC:0000874716-26-000050:0
1,758 shares@ US$634.571818.3% of flowCommon StockSEC:0000874716-26-000049:0
23,326 shares@ US$141.6023.4% of flowCommon StockSEC:0000874716-26-000043:0
2,693 shares@ US$661.541328.9% of flowCommon StockSEC:0000874716-26-000041:0
945 shares@ US$333.9020.2% of flowCommon StockSEC:0000874716-26-000032:0
1,191 shares@ US$141.6033.8% of flowCommon StockSEC:0000874716-26-000033:0
173 shares0Common StockSEC:0000874716-26-000027:0
117 shares0Common StockSEC:0000874716-26-000025:0
204 shares0Common StockSEC:0000874716-26-000023:0
176 shares0Common StockSEC:0000874716-26-000022:0
204 shares0Common StockSEC:0000874716-26-000021:0
92 shares0Common StockSEC:0000874716-26-000019:0
61 shares0Common StockSEC:0000874716-26-000018:0
148 shares0Common StockSEC:0000874716-26-000026:0
958 shares0Common StockSEC:0000874716-26-000024:0
55 shares0Common StockSEC:0000874716-26-000020:0
1,476 shares@ US$67.8530.9% of flowCommon StockSEC:0000874716-26-000005:0
36 shares@ US$670.4630.9% of flowCommon StockSEC:0000874716-26-000002:0
7,125 shares@ US$288.7834.2% of flowCommon StockSEC:0000874716-25-000168:0
25 of 241 declarations
About Idexx Laboratories INC /de
IDEXX Laboratories, Inc. (ticker: IDXX) is a U.S.-based company listed on the NASDAQ market in the United States. It is a global leader in veterinary diagnostics, practice software, and water microbiology testing. Founded in 1983 and headquartered in Westbrook, Maine, IDEXX has built a highly specialized healthcare franchise centered on companion animal medicine, recurring consumables, laboratory services, and software-enabled workflow solutions. The company’s positioning is anchored in innovation, high recurring revenue characteristics, and deep integration across instruments, reagents, reference lab services, and clinical software.
IDEXX operates through three reportable segments: Companion Animal Group (CAG), Water, and Livestock, Poultry and Dairy (LPD). CAG is the core earnings engine and includes point-of-care analyzers for veterinary clinics, diagnostic tests, imaging-related solutions, reference laboratory services, and practice management software. Products and platforms such as Catalyst, SediVue, and IDEXX reference lab services are designed to help veterinarians make faster and more confident medical decisions while improving clinic efficiency. The Water segment offers microbiological testing solutions used to monitor water safety, and LPD serves animal protein production markets with diagnostics for cattle, poultry, and swine.
Read moreShow less
From a competitive standpoint, IDEXX enjoys a strong market position thanks to its installed base, consumables-driven recurring revenue model, and broad product ecosystem. Management emphasizes that the combination of proprietary diagnostics, software integration, and lab services creates a differentiated customer proposition and meaningful switching costs. The company also has a broad international footprint: in 2025, about 36% of total revenue came from customers outside the United States, and IDEXX serves clients in more than 175 countries and territories.
Recent developments have reinforced the growth story. In first-quarter 2026, IDEXX reported revenue of $1.141 billion, up 14% as reported and 11% organically, with growth led by the Companion Animal Group. The company has continued to expand its diagnostic portfolio, including new cancer and renal testing offerings, while also broadening the Catalyst platform. Management commentary in recent releases highlights continued gains in consumables usage, installed base expansion, and international momentum. For investors, IDEXX represents a high-quality healthcare technology business with secular tailwinds from pet health spending, diagnostic penetration, and recurring revenue growth, all while being listed on NASDAQ in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
